Merck & Co., Inc. (MRK) Projects 21% Upside with $140 Price Target as Keytruda and New Vaccines Drive Growth

The article discusses Merck & Co., Inc. in the context of the best healthcare stocks favored by hedge funds. It highlights the growth potential of the healthcare sector amid economic challenges and provides insights into Merck's performance and investment outlook.